IR
IRD.O
—
NASDAQ
Biotechnology
Ird.O
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
255,5M USD
P/E
—
EV / Rev
18,7x
Div yield
—
Op margin
-359,1 %
ROE
-696,7 %
Net margin
-892,4 %
Debt / equity
0,07
Beta
—
52w range
—
Volume
—
Day range
—
Prev close
$3,84
Open
—
Next earnings
2026-10-28
Ex-dividend
—
TR 1Y
—
About
Opus Genetics Inc (IRD.O) is a biotechnology company operating within the Health Care sector, generating revenue from its biotech activities while currently incurring operating losses.
Business. Opus Genetics Inc (IRD.O) is a biotechnology company operating within the Health Care sector, generating revenue from its biotech activities while currently incurring operating losses.
Classification85 %
SectorHealth Care
Industry groupBiotechnology
Generated · model-assisted
Sell-side consensus
BUY19 analysts
19 buy0 hold0 sell
Avg 12m price target10,56
Analyst recommendations
19 analysts · consensus BuyBuy19
Hold0
Sell0
12-month price target
10,56
Consensus of sell-side coverage.
At a glance
Score
—
not yet scored
Valuation
—
valuation pending
Analysts→
Buy
19 analysts · indicative
Ownership→
AMERIPRISE FINANCIAL INC
largest disclosed fund holder
Profitability→
-696,7 %
return on equity
Quality
—
not yet scored
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
— missing data
News & coverage
0Sector rotation
Sector1D1Mvs mkt
Materials+2,3 %+6,6 %+1,7 %
Communication Services+2,2 %−5,5 %+1,6 %
Energy+0,6 %+3,3 %+0,0 %
Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %
Information Technology+0,6 %+6,7 %+0,0 %
Consumer Discretionary+0,4 %+7,6 %−0,2 %
Financials−0,3 %−2,8 %−0,9 %
Consumer Staples−0,4 %+2,5 %−1,0 %
Real Estate−0,7 %+10,9 %−1,3 %
Industrials−1,9 %−3,1 %−2,5 %
Utilities−1,9 %+28,2 %−2,5 %
Developing storylines
No tracked sagas currently linked to IRD.O. Browse all sagas →
Analysis
AI analysis
Generated · analysis pipeline · tier hybrid · as of 2026-08-04
↑ At a glance
Opportunity
— missing data
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Company
- EarningsQ3 2026 earnings (expected)2026-10-28 · estimated
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
— missing data
Signals & dispatch
peak dispatch · —
Composite-score breakdown
Synthesis
Business
Opus Genetics Inc (IRD.O) is a biotechnology company operating within the Health Care sector, generating revenue from its biotech activities while currently incurring operating losses.
Classification85 %
SectorHealth Care
Industry groupBiotechnology
AI synthesis
GENERATED— missing data
Key takeaways
- Strong liquidity position with $45.09 million in cash and equivalents, exceeding total liabilities.
- High valuation multiples, including a price-to-book ratio of 17.49 and EV-to-revenue of 18.73, reflect growth expectations.
- Significant unprofitability with net income of -$49.59 million and negative operating cash flow of -$35.25 million.
- Low debt-to-equity ratio of 0.07 indicates minimal leverage and conservative capital structure.
- Strong analyst support with a mean recommendation of 1.74 and a mean price target of $10.56.
- Lack of historical data and segment details limits the ability to assess growth trends and revenue concentration.
Bull / Bear case
analysis pipeline— missing data
In focus — financials by report
Quarterly
Annual
QUARTERLYFiled 2026-05-12
Q1 2026 · Quarter highlights
Revenue $2.2M, −50,6% YoY; Operating income −44,7% YoY.
Revenue$2.2M−50,6 % YoY
Operating income-$14.4M−44,7 % YoY
Net income-$65.5M−699,8 % YoY
Free cash flow-$65.5M−700,9 % YoY
EPS—
Operating cash flow-$12.7M−41,5 % YoY
Financials
Income statement
Revenue$2.2M
Gross profit—
Operating income-$14.4M
Net income-$65.5M
Margins
Gross margin—
Operating margin-665.9%
Net margin-3038.2%
FCF margin-3037.6%
Balance sheet
Total assets$66.8M
Total liabilities$87.9M
Total equity-$21.1M
Cash & equivalents$60.0M
Long-term debt$1.2M
Cash flow
Operating cash flow-$12.7M
CapEx—
Free cash flow-$65.5M
SBC—
P&L flow · revenue → net income
Highlights
- ▍Revenue $2.2M, −50,6% YoY
- ▍Operating income −44,7% YoY
- ▍Net income −699,8% YoY
- ▍Free cash flow −700,9% YoY
- ▍Net margin -3038.2%
QUARTERLYFiled 2026-03-10
Q4 2025 · Quarter highlights
Revenue $3.9M, −10,2% YoY; Operating income +69,9% YoY.
Revenue$3.9M−10,2 % YoY
Operating income-$11.5M+69,9 % YoY
Net income-$16.5M+53,0 % YoY
Free cash flow-$16.5M+53,0 % YoY
EPS—
Operating cash flow-$35.3M−37,8 % YoY
Financials
Income statement
Revenue$3.9M
Gross profit—
Operating income-$11.5M
Net income-$16.5M
Margins
Gross margin—
Operating margin-296.3%
Net margin-427.5%
FCF margin-427.2%
Balance sheet
Total assets$50.2M
Total liabilities$34.9M
Total equity$15.3M
Cash & equivalents$45.1M
Long-term debt$1.1M
Cash flow
Operating cash flow-$35.3M
CapEx—
Free cash flow-$16.5M
SBC—
P&L flow · revenue → net income
Highlights
- ▍Revenue $3.9M, −10,2% YoY
- ▍Operating income +69,9% YoY
- ▍Net income +53,0% YoY
- ▍Free cash flow +53,0% YoY
- ▍Net margin -427.5%
QUARTERLYFiled 2025-11-12
Q3 2025 · Quarter highlights
Revenue $3.1M, −20,4% YoY; Operating income −3,8% YoY.
Revenue$3.1M−20,4 % YoY
Operating income-$8.3M−3,8 % YoY
Net income-$17.5M−131,9 % YoY
Free cash flow-$17.4M−131,7 % YoY
EPS—
Operating cash flow-$25.4M−40,1 % YoY
Financials
Income statement
Revenue$3.1M
Gross profit—
Operating income-$8.3M
Net income-$17.5M
Margins
Gross margin—
Operating margin-269.9%
Net margin-566.9%
FCF margin-566.5%
Balance sheet
Total assets$36.1M
Total liabilities$30.2M
Total equity$6.0M
Cash & equivalents$30.8M
Long-term debt$1.1M
Cash flow
Operating cash flow-$25.4M
CapEx—
Free cash flow-$17.4M
SBC—
P&L flow · revenue → net income
Highlights
- ▍Revenue $3.1M, −20,4% YoY
- ▍Operating income −3,8% YoY
- ▍Net income −131,9% YoY
- ▍Free cash flow −131,7% YoY
- ▍Net margin -566.9%
QUARTERLYFiled 2025-08-13
Q2 2025 · Quarter highlights
Revenue $2.9M, +159,2% YoY; Operating income −6,9% YoY.
Revenue$2.9M+159,2 % YoY
Operating income-$8.9M−6,9 % YoY
Net income-$7.4M+4,4 % YoY
Free cash flow-$7.4M+4,6 % YoY
EPS—
Operating cash flow-$19.3M−48,1 % YoY
Financials
Income statement
Revenue$2.9M
Gross profit—
Operating income-$8.9M
Net income-$7.4M
Margins
Gross margin—
Operating margin-309.0%
Net margin-257.5%
FCF margin-257.0%
Balance sheet
Total assets$38.7M
Total liabilities$21.2M
Total equity$17.5M
Cash & equivalents$32.4M
Long-term debt$1.0M
Cash flow
Operating cash flow-$19.3M
CapEx—
Free cash flow-$7.4M
SBC—
P&L flow · revenue → net income
Highlights
- ▍Revenue $2.9M, +159,2% YoY
- ▍Operating income −6,9% YoY
- ▍Net income +4,4% YoY
- ▍Free cash flow +4,6% YoY
- ▍Net margin -257.5%
QUARTERLYFiled 2025-05-15
Q1 2025 · Quarter highlights
Revenue $4.4M; Operating income -$9.9M.
Revenue$4.4M
Operating income-$9.9M
Net income-$8.2M
Free cash flow-$8.2M
EPS—
Operating cash flow-$9.0M
Financials
Income statement
Revenue$4.4M
Gross profit—
Operating income-$9.9M
Net income-$8.2M
Margins
Gross margin—
Operating margin-227.2%
Net margin-187.5%
FCF margin-187.2%
Balance sheet
Total assets$48.2M
Total liabilities$24.3M
Total equity$23.9M
Cash & equivalents$41.8M
Long-term debt$0.00
Cash flow
Operating cash flow-$9.0M
CapEx—
Free cash flow-$8.2M
SBC—
P&L flow · revenue → net income
Highlights
- ▍Revenue $4.4M
- ▍Operating income -$9.9M
- ▍Net margin -187.5%
QUARTERLYFiled 2025-03-31
Q4 2024 · Quarter highlights
Revenue $4.3M; Operating income -$38.0M.
Revenue$4.3M
Operating income-$38.0M
Net income-$35.1M
Free cash flow-$35.1M
EPS—
Operating cash flow-$25.6M
Financials
Income statement
Revenue$4.3M
Gross profit—
Operating income-$38.0M
Net income-$35.1M
Margins
Gross margin—
Operating margin-884.0%
Net margin-816.7%
FCF margin-816.5%
Balance sheet
Total assets$36.9M
Total liabilities$11.3M
Total equity$25.6M
Cash & equivalents$30.3M
Long-term debt$0.00
Cash flow
Operating cash flow-$25.6M
CapEx—
Free cash flow-$35.1M
SBC—
P&L flow · revenue → net income
Highlights
- ▍Revenue $4.3M
- ▍Operating income -$38.0M
- ▍Net margin -816.7%
QUARTERLYFiled 2024-11-12
Q3 2024 · Quarter highlights
Revenue $3.9M; Operating income -$8.0M.
Revenue$3.9M
Operating income-$8.0M
Net income-$7.5M
Free cash flow-$7.5M
EPS—
Operating cash flow-$18.1M
Financials
Income statement
Revenue$3.9M
Gross profit—
Operating income-$8.0M
Net income-$7.5M
Margins
Gross margin—
Operating margin-207.1%
Net margin-194.6%
FCF margin-194.6%
Balance sheet
Total assets$40.4M
Total liabilities$6.1M
Total equity$34.3M
Cash & equivalents$36.6M
Long-term debt$0.00
Cash flow
Operating cash flow-$18.1M
CapEx—
Free cash flow-$7.5M
SBC—
P&L flow · revenue → net income
Highlights
- ▍Revenue $3.9M
- ▍Operating income -$8.0M
- ▍Net margin -194.6%
QUARTERLYFiled 2024-08-13
Q2 2024 · Quarter highlights
Revenue $1.1M; Operating income -$8.3M.
Revenue$1.1M
Operating income-$8.3M
Net income-$7.8M
Free cash flow-$7.8M
EPS—
Operating cash flow-$13.0M
Financials
Income statement
Revenue$1.1M
Gross profit—
Operating income-$8.3M
Net income-$7.8M
Margins
Gross margin—
Operating margin-748.9%
Net margin-698.3%
FCF margin-698.3%
Balance sheet
Total assets$44.8M
Total liabilities$4.2M
Total equity$40.6M
Cash & equivalents$41.4M
Long-term debt$0.00
Cash flow
Operating cash flow-$13.0M
CapEx—
Free cash flow-$7.8M
SBC—
P&L flow · revenue → net income
Highlights
- ▍Revenue $1.1M
- ▍Operating income -$8.3M
- ▍Net margin -698.3%
ANNUALFiled 2026-03-10
FY 2026 · Full-year highlights
Revenue $14.2M, +29,1% YoY; Operating income +37,8% YoY.
Revenue$14.2M+29,1 % YoY
Operating income-$38.6M+37,8 % YoY
Net income-$49.6M+13,8 % YoY
Free cash flow-$49.5M+13,9 % YoY
EPS—
Operating cash flow-$35.3M−37,8 % YoY
Financials
Income statement
Revenue$14.2M
Gross profit—
Operating income-$38.6M
Net income-$49.6M
Margins
Gross margin—
Operating margin-271.9%
Net margin-349.3%
FCF margin-349.0%
Balance sheet
Total assets$50.2M
Total liabilities$34.9M
Total equity$15.3M
Cash & equivalents$45.1M
Long-term debt$1.1M
Cash flow
Operating cash flow-$35.3M
CapEx—
Free cash flow-$49.5M
SBC—
P&L flow · revenue → net income
Highlights
- ▍Revenue $14.2M, +29,1% YoY
- ▍Operating income +37,8% YoY
- ▍Net income +13,8% YoY
- ▍Free cash flow +13,9% YoY
- ▍Net margin -349.3%
ANNUALFiled 2025-03-31
FY 2025 · Full-year highlights
Revenue $11.0M, −42,3% YoY; Operating income −487,7% YoY.
Revenue$11.0M−42,3 % YoY
Operating income-$62.1M−487,7 % YoY
Net income-$57.5M−476,1 % YoY
Free cash flow-$57.5M−476,4 % YoY
EPS—
Operating cash flow-$25.6M−2 200,0 % YoY
Financials
Income statement
Revenue$11.0M
Gross profit—
Operating income-$62.1M
Net income-$57.5M
Margins
Gross margin—
Operating margin-564.7%
Net margin-523.4%
FCF margin-523.3%
Balance sheet
Total assets$36.9M
Total liabilities$11.3M
Total equity$25.6M
Cash & equivalents$30.3M
Long-term debt$0.00
Cash flow
Operating cash flow-$25.6M
CapEx—
Free cash flow-$57.5M
SBC—
P&L flow · revenue → net income
Highlights
- ▍Revenue $11.0M, −42,3% YoY
- ▍Operating income −487,7% YoY
- ▍Net income −476,1% YoY
- ▍Free cash flow −476,4% YoY
- ▍Net margin -523.4%
ANNUALFiled 2024-03-08
FY 2024 · Full-year highlights
Revenue $19.0M, −52,2% YoY; Operating income −158,0% YoY.
Revenue$19.0M−52,2 % YoY
Operating income-$10.6M−158,0 % YoY
Net income-$10.0M−155,8 % YoY
Free cash flow-$10.0M−155,8 % YoY
EPS—
Operating cash flow-$1.1M−107,8 % YoY
Financials
Income statement
Revenue$19.0M
Gross profit—
Operating income-$10.6M
Net income-$10.0M
Margins
Gross margin—
Operating margin-55.5%
Net margin-52.4%
FCF margin-52.4%
Balance sheet
Total assets$53.9M
Total liabilities$4.0M
Total equity$49.9M
Cash & equivalents$50.5M
Long-term debt$0.00
Cash flow
Operating cash flow-$1.1M
CapEx—
Free cash flow-$10.0M
SBC—
P&L flow · revenue → net income
Highlights
- ▍Revenue $19.0M, −52,2% YoY
- ▍Operating income −158,0% YoY
- ▍Net income −155,8% YoY
- ▍Free cash flow −155,8% YoY
- ▍Net margin -52.4%
ANNUALFiled 2023-03-30
FY 2023 · Full-year highlights
Revenue $39.9M, +6 665,7% YoY; Operating income +180,3% YoY.
Revenue$39.9M+6 665,7 % YoY
Operating income$18.2M+180,3 % YoY
Net income$17.9M+131,6 % YoY
Free cash flow$17.9M+131,6 % YoY
EPS—
Operating cash flow$14.3M+173,9 % YoY
Financials
Income statement
Revenue$39.9M
Gross profit—
Operating income$18.2M
Net income$17.9M
Margins
Gross margin—
Operating margin45.7%
Net margin44.9%
FCF margin44.9%
Balance sheet
Total assets$49.0M
Total liabilities$2.8M
Total equity$46.2M
Cash & equivalents$42.6M
Long-term debt$0.00
Cash flow
Operating cash flow$14.3M
CapEx—
Free cash flow$17.9M
SBC—
P&L flow · revenue → net income
Highlights
- ▍Revenue $39.9M, +6 665,7% YoY
- ▍Operating income +180,3% YoY
- ▍Net income +131,6% YoY
- ▍Free cash flow +131,6% YoY
- ▍Net margin 44.9%
Valuation TTM
Market price
$3,65
Market cap
$268.4M
Enterprise valueⓘ
$224.4M
P/Eⓘ
—
Non-GAAP P/Eⓘ
—
EV / Revenueⓘ
18.7x
EV / Op incomeⓘ
—
EV / OCFⓘ
—
P / Bⓘ
17.5x
P / Tangible bookⓘ
17.5x
Tangible book
$15.3M
Net cashⓘ
$44.0M
Current ratioⓘ
—
Debt / equityⓘ
0.1
ROAⓘ
-2.1%
ROEⓘ
-7.0%
Cash conversionⓘ
33.0%
CapEx / revenueⓘ
—
SBC / revenueⓘ
—
Dilution ratioⓘ
0.0%
Revenue by segment
Business relationships
Business relationships1 disclosed relationship · 1 type · extracted from filings & disclosures
Partners1
VIATRIS INC.VTRS.OPartner98%Source ↗
Supply chain
Vendors → IRD ↔ Partners → Customers · click any node to drill
1 mention in 10-K0 from corporate websites0 from news dispatches
Updated 2026-06-24Peer comparison
— missing data
Market position
Stress test
— missing data
Predictor forecast
Next quarternear-term
Earnings · next quarterconf 33 %
EPS
Consensus EPS
-1,08
Predicted surprise
-0,03
Beat probability
33 %
Analysts
19
Other metrics
Revenue
—
no estimate
Segment revenue
—
no estimate
Margin
—
no estimate
Segment margin
—
no estimate
as of 2026-07-31 · Earnings Surprise V1
Period note: consensus is not fiscal-period-aligned at source — read as consensus vs the last reported actual, not a calibrated same-quarter surprise.
Full fiscal year~1 year ahead
Full fiscal year · our forecast vs guidance vs consensus
| Metric | Our forecast | Guidance | Consensus |
|---|---|---|---|
| EPS | —no estimate | —no estimate | -1,08 |
| Revenue | —no estimate | —no estimate | 13,4M USD |
| Operating income | —no estimate | —no estimate | -52,8M USD |
Full-year consensus mean (period as reported by source) · consensus in USD. Company-level full-year forecast and management guidance are not yet modelled at scale — shown as "no estimate", never inferred.
Probabilistic model output — not investment advice. · generated 2026-08-04
Options
— missing data
Short squeeze
— missing data
Earnings-call key lines
— missing data
Consensus distribution
sell-side coverageRecommendation distribution19 analysts
Strong buy5
Buy14
Hold0
Sell0
Strong sell0
12-month price target$10,56 · Median $10,00
Low $8,00High $16,00
Operating income · consensus-52,8M USD
EPS surprise
+26,2 %
reported vs consensus · beat
Revenue surprise
+6,2 %
reported vs consensus · beat
Estimate revisions
consensus EPS · 26-week trend— missing data
Sell-side observations
Low$8,00
Mean$10,56
Median$10,00
High$16,00
Spot$3,65
+188.8 %implied to mean12-month sell-side price targets · ▲ spot
Themes
— missing data
ESG
— missing data
Risk factors
Dilution riskLow
Liquidity riskLow
Filing-based flags
- No immediate filing-based liquidity or dilution flags were detected.
Benchmarks vs cohort
Op Margin-359,1 %Below median
Net Margin-892,4 %Below median
ROE-696,7 %Bottom quartile
D/E0,07Bottom quartile
Cash Conv0,33Below median
Corporate actions / M&A
— missing data
FX exposure
— missing data
Comparable transactions
— missing data
Derivatives & instruments
— missing data
Actions
Ask Handelsavisen
— missing data
Data sources
- Reference data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
How metrics are computed
- Cash Conversion Ratiooperating_cash_flow / net_income
- Market Priceinput from market-data provider (delayed close or quote-shim mid)
- Ev To Revenueenterprise_value / revenue
- Net Cashcash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
- Return On Equitynet_income / total_equity
- Market Capmarket_price * shares_outstanding_diluted
Source documents
- Opus Genetics, Inc. Market data — financials · 2026-07-31
- reconciler_enqueue (reconciler) on IRD.O · 2026-07-31
- Opus Genetics Inc Market data — analyst estimates · 2026-07-31
- IRD.O HA canonical relationships · 2026-07-31
Ownership & reference
Top holders
- Institutional Investor · as of 2026-03-310,00 %$2M
- Investment Managers · as of 2026-03-310,00 %$1M
- Investment Managers · as of 2026-03-310,00 %$1M
- Investment Managers · as of 2026-03-310,00 %$2M
- Investment Managers · as of 2025-12-310,00 %$5M
- Investment Managers · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$1M
- Brokerage Firms · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2024-06-300,00 %$0M
- Brokerage Firms · as of 2026-03-310,00 %$0M
- Institutional Investor · as of 2026-03-310,00 %$0M
Leadership
- Benjamin R. YerxaPresident, Director
Insider activity
Net selling0 buys · 15 sellsnet -$7,9M14 insiders · last 365d
- Director, Chief Executive Officer · Common StockSold 9 475 @ $2,95$28K · 2026-07-23
- Chief Financial Officer · Common StockSold 7 783 @ $2,95$23K · 2026-07-23
- Chief Operating Officer · Common StockSold 4 644 @ $2,94$14K · 2026-07-23
- Director, President · Common StockSold 7 429 @ $2,97$22K · 2026-07-23
- Director, See Remarks · Common StockSold 1 700 000 @ $4,35$7,4M · 2026-05-18
- Director, President · Common StockSold 7 470 @ $5,24$39K · 2026-04-23
- Chief Operating Officer · Common StockSold 4 697 @ $5,22$25K · 2026-04-23
- Head of Fin. Quality Assurance · Common StockSold 1 641 @ $5,20$9K · 2026-04-23
- Director, Chief Executive Officer · Common StockSold 9 511 @ $5,22$50K · 2026-04-23
- Chief Scientific & Dev. Ofc. · Common StockSold 7 542 @ $5,19$39K · 2026-04-23
- Chief Financial Officer · Common StockSold 7 842 @ $5,18$41K · 2026-04-23
- Director · Common StockOther 24 367 · 2026-04-20
- Director · Common StockOther 24 367 · 2026-04-20
- Director · Common StockOther 24 367 · 2026-04-20
- Director · Common StockOther 24 367 · 2026-04-20
- Director · Common StockOther 24 367 · 2026-04-20
- Director · Common StockOther 24 367 · 2026-04-20
- Director · Common StockOther 24 367 · 2026-04-20
- Chief Operating Officer · Common StockSold 3 719 @ $5,25$20K · 2026-03-16
- Head of Fin. Quality Assurance · Common StockSold 2 816 @ $5,25$15K · 2026-03-16
- Director, Chief Executive Officer · Common StockSold 24 438 @ $5,21$127K · 2026-03-16
- Chief Scientific & Dev. Ofc. · Common StockSold 3 719 @ $5,12$19K · 2026-03-16
- Chief Scientific & Dev. Ofc. · Common StockOther 5 313 @ $3,39$18K · 2026-02-12
- Chief Operating Officer · Common StockOther 250 000 · 2026-01-22
- Director, Chief Executive Officer · Common StockOther 483 639 · 2026-01-22
Short positioning
10.3Mshares short+24.8% vs prior
12.52days to cover
29.6%short of daily vol
100fails-to-deliver
as of 2026-07-15 · short-interest report (free)
Geographic breakdown
— missing data
Listings · one canonical issuer
all listings resolve to the canonical
IRD.OCanonical
NASDAQ · USD
Intel & risk
peak dispatch · —
OSINT findings
Dilution riskLow
Liquidity riskLow
No immediate filing-based liquidity or dilution flags were detected.
Relationship graph
This companySectorPartners
Evidence & claims
From filings & derived data- Total assets (YoY) (2025-12-31 vs 2024-12-31): 36.3%Derived (calculated)
- Total liabilities (YoY) (2025-12-31 vs 2024-12-31): 208.9%Derived (calculated)
- Cash & equivalents (YoY) (2025-12-31 vs 2024-12-31): 48.7%Derived (calculated)
- Return on equity (FY 2025-12-31): -323.1%Derived (calculated)
- Shareholders' equity (YoY) (2025-12-31 vs 2024-12-31): 128.3%Derived (calculated)
- Revenue (YoY) (2025-12-31 vs 2024-12-31): 29.1%Derived (calculated)
- Operating income (YoY) (2025-12-31 vs 2024-12-31): 37.8%Derived (calculated)
- Operating cash flow (YoY) (2025-12-31 vs 2024-12-31): -37.8%Derived (calculated)
- Net income (YoY) (2025-12-31 vs 2024-12-31): 13.8%Derived (calculated)
- EPS (diluted) (YoY) (2025-12-31 vs 2024-12-31): 62.8%Derived (calculated)
- EPS (basic) (YoY) (2025-12-31 vs 2024-12-31): 62.8%Derived (calculated)
- Debt-to-equity (FY 2025-12-31): 2.27xDerived (calculated)
- Current ratio (FY 2025-12-31): 6.43xDerived (calculated)
- Net margin (FY 2025-12-31): -349.3%Derived (calculated)
- Return on assets (FY 2025-12-31): -98.7%Derived (calculated)
- Operating income (annual): USD -38.6MSEC XBRL filing
- EPS (diluted) (annual): USD-PER-SHARES -1SEC XBRL filing
- EPS (basic) (annual): USD-PER-SHARES -1SEC XBRL filing
- Operating cash flow (annual): USD -35.25MSEC XBRL filing
- Total liabilities (annual): USD 34.9MSEC XBRL filing
- Cash & equivalents (annual): USD 45.09MSEC XBRL filing
- Revenue (annual): USD 14.2MSEC XBRL filing
- Pre-tax income (annual): USD -49.59MSEC XBRL filing
- Shares outstanding (annual): 69.89MSEC XBRL filing
Showing 24 of 60 surfaced claims.
Atomic claims from regulatory filings and derived calculations. Provenance shown as source kind only.
The Thread
Everything we know, in order2026-10-28EVENTUpcomingQ3 2026 earnings (expected) estimated date
2026-07-23INSIDERMagrath George sold 9.5k sh — Director, Chief Executive Officer ~$28k
2026-07-23INSIDERGagnon Robert E. sold 7.8k sh — Chief Financial Officer ~$23k
2026-07-23INSIDERSCHACHLE JOSEPH K sold 4.6k sh — Chief Operating Officer ~$14k
2026-07-23INSIDERYERXA BENJAMIN R sold 7.4k sh — Director, President ~$22k
2026-05-18 00:00 UTCINSIDER1 insider transaction — 2026-05 · net sell $7.4M
2026-05-18 00:00 UTCINSIDER1 insider transaction — 2026-05 · net sell $7.4M
2026-05-18INSIDERFoundation Fighting Blindness Retinal Degeneration Fund sold 1.70M sh — Director, See Remarks ~$7.39M
2026-05-12 07:00 UTCEARNINGSQuarterly results — Q1 2026 Revenue USD 2.2M · Net USD -65.5M
2026-04-23 00:00 UTCINSIDER13 insider transactions — 2026-04 · net sell $202k
2026-04-23 00:00 UTCINSIDER13 insider transactions — 2026-04 · net sell $202k
2026-04-23INSIDERYERXA BENJAMIN R sold 7.5k sh — Director, President ~$39k
2026-04-23INSIDERSCHACHLE JOSEPH K sold 4.7k sh — Chief Operating Officer ~$25k
2026-04-23INSIDERZaremba Rabourn Amy sold 1.6k sh — Head of Fin. Quality Assurance ~$9k
2026-04-23INSIDERMagrath George sold 9.5k sh — Director, Chief Executive Officer ~$50k
2026-04-23INSIDERJayagopal Ashwath sold 7.5k sh — Chief Scientific & Dev. Ofc. ~$39k
2026-04-23INSIDERGagnon Robert E. sold 7.8k sh — Chief Financial Officer ~$41k
2026-04-20INSIDERRodgers Richard J transacted 24.4k sh — Director
2026-04-20INSIDERMANUSO JAMES S J transacted 24.4k sh — Director
2026-04-20INSIDERGraves Adrienne L transacted 24.4k sh — Director
2026-04-20INSIDERGallagher Cam transacted 24.4k sh — Director
2026-04-20INSIDERBenton Susan transacted 24.4k sh — Director
2026-04-20INSIDERBennett Jean transacted 24.4k sh — Director
2026-04-20INSIDERAinsworth Sean transacted 24.4k sh — Director
2026-03-16 00:00 UTCINSIDER4 insider transactions — 2026-03 · net sell $181k
2026-03-16 00:00 UTCINSIDER4 insider transactions — 2026-03 · net sell $181k
2026-03-16INSIDERSCHACHLE JOSEPH K sold 3.7k sh — Chief Operating Officer ~$20k
2026-03-16INSIDERZaremba Rabourn Amy sold 2.8k sh — Head of Fin. Quality Assurance ~$15k
2026-03-16INSIDERMagrath George sold 24.4k sh — Director, Chief Executive Officer ~$127k
2026-03-16INSIDERJayagopal Ashwath sold 3.7k sh — Chief Scientific & Dev. Ofc. ~$19k
Showing the 40 most recent of 59 entries.
The entity's full life in the product — typed, chronological, joined across Newspaper, Platform and Data. Our memory, made visible.
Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04
Reference data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data
Premium coverage